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A Field of Myocardial-Endocardial NFAT Signaling
Underlies Heart Valve Morphogenesis
1995). This process, termed endocardial-mesenchymal
transformation (EMT), occurs in the atrioventricular ca-
nal at day 9 of mouse embryonic development and re-
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quires signaling between myocardial and endocardialIsabella A. Graef,1 and Gerald R. Crabtree1,*
cells. Once transformed, the mesenchymal cells prolifer-1Departments of Pathology and Developmental
ate and invade the cardiac jelly, a basement membrane-Biology
like substance elaborated by the myocardial cells. AHoward Hughes Medical Institute
second process, which is even less well understood,2 Cardiovascular Division
begins after EMT. The endocardial cushion area elon-Department of Medicine
gates and undergoes continuous remodeling that even-Stanford University Medical School
tually refines the primitive cushion into thin elongatedStanford, California 94305
valve leaflets.
Several signaling pathways have been implicated in
heart valve morphogenesis. Studies with neutralizingSummary
antibodies and antisense RNA indicate that TGF- sig-
naling is essential for EMT in the chick (Eisenberg andThe delicate leaflets that make up vertebrate heart
Markwald, 1995; Nakajima et al., 2000). However, proba-valves are essential for our moment-to-moment exis-
bly due to functional redundancy in the mammalian sys-tence. Abnormalities of valve formation are the most
tem, mice with single mutations in the TGF- familycommon serious human congenital defect. Despite
members or their receptors do not have impaired EMT.their importance, relatively little is known about valve
The Wnt/-catenin pathway is essential for EMT in ze-development. We show that the initiation of heart valve
brafish (Hurlstone et al., 2003). In mice, however, Wntmorphogenesis in mice requires calcineurin/NFAT to
plays an essential early role in cardiac myogenesisrepress VEGF expression in the myocardium underly-
(Olson and Schneider, 2003), thus obscuring any latering the site of prospective valve formation. This repres-
roles in heart valve formation. Also, Notch signaling hassion of VEGF at E9 is essential for endocardial cells
recently been shown to promote EMT in mice (Timmer-to transform into mesenchymal cells. Later, at E11, a
man et al., 2004). EGF-related growth factors and theirsecond wave of calcineurin/NFAT signaling is required
receptors are important in regulating heart valve forma-in the endocardium, adjacent to the earlier myocardial
tion in mice. Loss of endocardial HB-EGF or EGFR re-site of NFAT action, to direct valvular elongation and
sults in abnormal hyperplasia of cushion mesenchymalrefinement. Thus, NFAT signaling functions sequen-
cells (Chen et al., 2000; Iwamoto et al., 2003; Jacksontially from myocardium to endocardium within a valvu-
et al., 2003). Lack of endocardial neuregulin-1 or cushionlar morphogenetic field to initiate and perpetuate
mesenchymal ErbB3 results in severe mesenchymal hy-embryonic valve formation. This mechanism also op-
poplasia in the cushion area (Camenisch et al., 2002;erates in zebrafish, indicating a conserved role for
Erickson et al., 1997; Meyer and Birchmeier, 1995). Rascalcineurin/NFAT signaling in vertebrate heart valve
signaling is also crucial for cushion mesenchymal devel-morphogenesis.
opment. Loss of endothelial neurofibromin-1, which in-
activates Ras, results in hyperplasia of cushion mesen-Introduction
chymal cells (Gitler et al., 2003; Lakkis and Epstein,
1998).
The creation of four valves, designed to open and shut
Lethal defects in heart valve formation are also ob-
once every second for perhaps 80 years with near-per-
served in mice lacking NFATc1, although the basis of
fect fluid dynamics, is a considerable challenge for the the defect has been difficult to define (de la Pompa et
developing organism. That such a precise develop- al., 1998; Ranger et al., 1998). Calcineurin/NFATc signal-
mental process frequently goes awry is not surprising. ing is activated by a wide variety of receptors and ion
Indeed, congenital aortic valve defects occur in 2%–3% channels (Crabtree and Olson, 2002). These receptors
of the population (Brickner et al., 2000; Fedak et al., lead to elevated intracellular Ca2 and the activation of
2002). Pulmonic valvular disease also constitutes 10% calcineurin, a Ca2/calmodulin-dependent phosphatase
of all congenital heart disease in adults (Brickner et al., composed of a regulatory (CnB) and a catalytic (CnA)
2000). The subtler of these congenital defects do not subunit, each encoded by gene families (Klee et al.,
produce disease until midlife, when they generate signif- 1998). Activated calcineurin dephosphorylates the NFATc
icant morbidity and mortality. Congenital valve disease proteins (c1 to c4), exposing nuclear localization signals
thus provides an example of how aberrant embryonic and causing NFATc to translocate into the nucleus
processes can lead to disease in mid and late adulthood. (Beals et al., 1997; Clipstone and Crabtree, 1992; Flana-
Heart valve formation is initiated when the endocardial gan et al., 1991). Once in the nucleus, NFATc proteins
cells within the endocardial cushions delaminate from cooperate with nuclear partners (NFATn) to form NFAT
the surface layer and undergo transdifferentiation to be- transcriptional complexes on target genes (Crabtree,
come mesenchymal cells (Eisenberg and Markwald, 1989; Flanagan et al., 1991). The activity of calcineurin
and NFATc function can be specifically blocked by the
immunosuppressive drugs cyclosporine A and FK506*Correspondence: crabtree@stanford.edu
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Figure 1. Endocardial Cnb1/NFATc1 Regulates Heart Valve Elongation
Histological examination of aortic (A, D, G, J, and M), pulmonic (B, E, H, K, and N), mitral and tricuspid (C, F, I, L, and O) valve formation in
Cnb1 and NFATc1 mutants. (A–C) Valve morphology at E13.5 in wild-type embryos. (D–F) Valve morphology at E13.5 in embryos lacking
endocardial Cnb1. (G–I) Valve morphology at E13.5 in NFATc1/ mutant embryos. (J–L) Valve morphology at E15.5 in wild-type embryos.
(M–O) Valve morphology at E15.5 in NFATc1/; Tie2-NFATc1 mice. RV, right ventricle; LV, left ventricle; Ao, aorta; PA, pulmonary artery; AV,
aortic valve; PV, pulmonic valve; MV, mitral valve; TV, tricuspid valve.
(Emmel et al., 1989; Liu et al., 1991). The developmental sulting in cytoplasmic localization of NFATc1 (Supple-
mental Figures S1C–S1F) (Hugo Nomenclature, see Ex-specificity of NFAT signaling is thought to arise from
the assembly of NFAT complexes on DNA from distinct perimental Procedures).
The angiogenic defects observed in germline Cnb1combinations of NFATc and NFATn proteins (Flanagan
et al., 1991; Wolfe et al., 1997). mutants (Graef et al., 2001) were not observed when
Cnb1 function was removed from the endothelium. In-Our studies show that heart valve morphogenesis is
initiated at E9 by calcineurin/NFATc signaling in the stead, mice with disrupted endocardial Cnb1 displayed
valvular defects almost identical to NFATc1/ micemyocardium, which represses the expression of VEGF,
a potent inhibitor of EMT. Two days later at E11, cal- (Figures 1A–1I) and died at the same time between E13.5
and E14.5 (see Supplemental Figures S2A and S2B oncineurin and NFATc1 are essential in the endocardium to
direct the remodeling of valvular leaflets. This sequential the Cell web site). The semilunar (aortic and pulmonic)
and atrioventricular (mitral and tricuspid) valves in themyocardial-endocardial NFAT signaling orchestrates
the molecular and cellular events required to both initiate mutants lacking endocardial calcineurin remained small,
failing to elongate and remodel to form thin valve leafletsand perpetuate heart valve morphogenesis.
(Figures 1A–1F). Severe regurgitation was observed in
the hearts of mutant embryos at E13.5–E14.5, indicatingResults
the functional insufficiency of the blunted valve leaflets
that could not close properly (Figures 1A–1F). AlthoughEndocardial Calcineurin Is Essential
for Valve Morphogenesis the valves failed to elongate, mesenchymal cells were
present in both the semilunar and atrioventricular valvesGermline deficiency of Cnb1 results in lethal defects in
vascular patterning at E10.5 (Graef et al., 2001). To better of embryos lacking endocardial Cnb1 or NFATc1 (Fig-
ures 1D–1F), indicating that calcineurin and NFATc1understand the function of calcineurin in endothelial
cells, we inactivated calcineurin specifically in these activity in the endocardium are not required for endocar-
dial-mesenchymal transformation. Myocardial develop-cells using Tie2-Cre mice and mice bearing a floxed
allele of Cnb1 (Kisanuki et al., 2001; Neilson et al., 2004). ment appeared normal in these mutants (data not
shown). These findings provide genetic evidence thatCre-mediated recombination was observed in the endo-
thelium by E8 (see Supplemental Figure S1B on the Cell endocardial calcineurin is specifically required to regu-
late NFATc1 activity during valvular elongation and re-web site at http://www.cell.com/cgi/content/full/118/5/
649/DC1). By E9, Cnb1 protein was undetectable in en- modeling.
docardial cells, and NFATc1 protein in these cells was
localized to the cytoplasm, consistent with a loss of Endocardial Calcineurin Regulates Valvular
Morphogenesis through NFATc1calcineurin phosphatase activity (data not shown). Cnb1
protein was eliminated at E10 in both the endocardium To define the site of action of NFATc1, we generated a
transgenic mouse line expressing the  isoform of wild-and the endocardially-derived cushion mesenchyme, re-
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Figure 2. Endocardial Cnb1/NFATc1 Is Required at E11 for Heart Valve Elongation
Histological examination of aortic (A, D, G, and J), pulmonic (B, E, H, and K), mitral and tricuspid (C, F, I, and L) valve formation in embryos
isolated from CD-1 mothers injected with CsA (100 g/g subQ bid) at various stages of development. (A–C) E13 valve morphology of embryos
exposed to CsA at E10. (D–F) E13 valve morphology of embryos exposed to CsA at E11. (G–I) E13 valve morphology of embryos exposed to
CsA at E12. (J–L) E13 valve morphology of control embryos exposed to PBS at E11. (M–P) Immunostaining of NFATc1 (green) in wild-type
embryos from E9.5 to E12.5. A, V, and C represent atrial, ventricular, and cushion endocardium, respectively. NFATc1 expression becomes
restricted to cushion areas by E11, and its cardiac expression becomes undetectable by E13. (Q) Critical time window during which NFATc1
is crucial for heart valve elongation.
type NFATc1 in the endocardium using the Tie2 pro- shown). Viability of NFATc1/ mice was fully rescued
(Supplemental Figure S2D), indicating that NFATc1moter (Tie2-NFATc1). Expressing NFATc1 in the endo-
cardium rescued the valvular defects in NFATc1/ mice, functions specifically in the endocardium to regulate
valve morphogenesis. In contrast, transgenic endocar-resulting in well-formed semilunar and atrioventricular
valves at E15.5 (Figures 1M–1O), birth, and P21 (data not dial expression of NFATc1 failed to rescue the valvular
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defects observed in mice deficient in endocardial Cnb1 mesenchymal transformation of endocardial cushions
explanted from E9.5 embryos (20–25 somite pairs) (Fig-(Supplemental Figure S2E). This result shows that cal-
cineurin regulates NFATc1 function in the endocardium, ures 3C–3E). In contrast, CsA had no effect on the out-
growth of mesenchymal cells from endocardial cushionsconsistent with the cytoplasmic localization of NFATc1
in embryos lacking endocardial Cnb1. explanted from E10.5 embryos (35–39 somites) after
EMT had begun (Figure 3E), indicating that CsA does
not inhibit mesenchymal cell proliferation or migration.Endocardial Calcineurin Is Required In Vivo
Instead, CsA specifically inhibits the initiation of endo-at Day 11 of Embryonic Development
cardial-to-mesenchymal transformation at E9.5. Consis-for Heart Valve Remodeling
tent with this conclusion, cushion explants from E9.75–Cyclosporine A (CsA) crosses the placenta and blocks
E10.0 embryos (25–35 somites) showed an intermediateall detectable calcineurin activity in the embryos of in-
response to CsA treatment (Figure 3E).jected mothers (Graef et al., 2001). We injected pregnant
Since calcineurin is present in both the endocardialwild-type mice with CsA between E10 and E13 and ex-
and myocardial layers of the E9.5 cushion explants, cal-amined heart valve morphology of the embryos at E13
cineurin signaling in either or both tissues could be re-to define the time window during which calcineurin/
quired for EMT. To differentiate between these possibili-NFATc1 is required for heart valve remodeling. Embryos
ties, we explanted E9.5 endocardial cushions fromfrom mothers injected at either E10 or E12 were viable
embryos lacking either endocardial Cnb1 or NFATc1 inand showed minimal valve abnormalities at E13.5 (Fig-
the gel culture system. Consistent with our observationsures 2A–2C and 2G–2I). In contrast, CsA treatment at
of normal cushion mesenchyme at E10 in these mutantsE11 resulted in valvular defects nearly identical to those
in vivo (Supplemental Figures S3A–S3C), both mutantof embryos lacking either NFATc1 or endocardial Cnb1
explants underwent normal EMT in vitro (Figure 3E),and led to embryonic lethality between E13 and E14
indicating that neither calcineurin nor NFATc1 was re-(compare Figures 2D–2F with Figures 1D–1I) (Supple-
quired in the endocardium for EMT. Given that cal-mental Figure S2C). The semilunar valves remained
cineurin was required for EMT, but endocardial cal-primitive bulges in the outflow tracts, and the atrioven-
cineurin/NFATc activity was dispensable for EMT, thesetricular valve leaflets were blunted in morphology (com-
data strongly indicate that calcineurin signaling in thepare Figures 2D–2F to Figures 2J–2L). The cardiac out-
myocardium is essential for EMT.flow tract, however, septated normally into aortic and
To further understand these EMT defects, we studiedpulmonary arteries, suggesting that the effect of CsA at
the endocardial cushions in E10.75 embryos with nullE11 on valve development is specific and is not due to
mutations in NFATc2, c3, and c4 (Graef et al., 2003).general developmental retardation. The recapitulation
Control embryos lacking NFATc2 and c4 had abundantof endocardial Cnb1/ or NFATc1/ valvular pheno-
mesenchymal cells in the cushion areas in both the atrio-types by CsA treatment at E11 thus indicates that cal-
ventricular canal and cardiac outflow tract (Figures 3Fcineurin/NFATc1 signaling is essential beginning at E11
and 3H). However, c2/c3/c4 triple mutant embryos hadin the endocardium for elongation and refinement of
significantly reduced numbers of mesenchymal cells inthe developing heart valves. The E11 requirement of
the atrioventricular canal and the cardiac outflow tractendocardial calcineurin/NFATc1 signaling corresponds
(Figures 3G and 3I), similar to the Cnb1 null mutantsto the time at which NFATc1 expression becomes re-
(data not shown). In addition to cushion defects, thestricted to the cushion endocardium where valve forma-
c2/c3/c4 mutants had abnormally thinned myocardium,tion occurs (Figures 2M–2Q). However, the endocardial
consistent with a role of calcineurin/NFATc in myocar-calcineurin/NFATc1 has no role in the EMT, even though
dial development and hypertrophy (Molkentin et al.,NFATc1 is specifically expressed in the endocardial cells
1998). These data, coupled with the observation thatundergoing this process (note the normal EMT in em-
EMT occurred normally in embryos lacking Cnb1 orbryos lacking NFATc1 and endocardial Cnb1; Figure 3E
NFATc1 in the endocardium, indicate that NFATc2/3/4and Supplemental Figures S3A–S3C). These observa-
act outside of the endocardium and function in the myo-tions raise the question of how EMT is controlled within
cardium to direct EMT in the cushion area. We concludethe area of endocardial NFATc1 expression.
that Cnb1 regulates NFATc2/c3/c4 in the myocardium
to induce mesenchymal transformation of the endocar-Myocardial Calcineurin Signaling through
dium overlying the cushions.NFATc2/3/4 Is Essential for Endocardial-to-
Mesenchymal Transformation
To study the role of calcineurin signaling in the transfor- Myocardial Calcineurin Signaling at E9 Suppresses
the Production of a Soluble Factormation process, we employed an in vitro EMT assay
(Runyan and Markwald, 1983). The E9 endocardial cush- that Inhibits Mesenchymal Transformation
To define the period in which calcineurin/NFATc is re-ion, consisting of endocardial and myocardial cell layers,
was dissected from the atrioventricular canal and ex- quired for EMT in vivo, we exposed developing embryos
to CsA in utero at different stages. Embryos exposed toplanted on a collagen gel (Figures 3A and 3B). Endocar-
dial cells in the explants normally undergo mesenchymal CsA at E9 showed reduced EMT (Figure 3J). In contrast,
embryos exposed to CsA at either E8 or E10 showedtransformation, proliferate, and migrate into the collagen
gel within 24–48 hr. Enumerating morphologically dis- normal EMT in the cushion areas (data not shown). The
differential sensitivity of E9 and E10 embryos to CsAtinct mesenchymal cells at 24–48 hr provides a semi-
quantitative assay of EMT and the proliferation/migra- injection parallels the differential effects of CsA on E9.5
and E10.5 cushion explants in vitro (see above), indicat-tion of mesenchymal cells. CsA completely inhibited
NFAT Signaling in Heart Valve Morphogenesis
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Figure 3. Calcineurin Signaling in the Myocardium Is Required at E9 for Endocardial Mesenchymal Transformation
(A and B) An in vitro EMT assay in which the endocardial cushion from the atrioventricular (AV) canal is explanted and cultured on collagen gel.
(C) Outgrowth of spindle-shaped mesenchymal cells 24–48 hr after explantation of an E9.5 endocardial cushion.
(D) Treatment of E9.5 cushion explants with CsA inhibits EMT. The endocardial cells remain polygonal and do not transform to spindle-shaped
mesenchymal cells.
(E) Quantitation of mesenchymal cells outgrowth in EMT assay.
(F and H) Histological examination of EMT (circles) in AVC and OFT of control embryos at E10.75.
(G and I) Histological examination of EMT (circles) in AVC and OFT of NFATc2/c3/c4 triple null mutants at E10.75.
(J and K) Histological examination of EMT in AVC of embryos exposed to CsA (100 ug/g ip bid) or PBS at E9. AVC, atrioventricular cushion;
OFT, outflow tract.
ing that myocardial calcineurin signaling is crucial at E9 studied the ability of endocardial cushions derived from
Cnb1 null embryos to control EMT of adjacent wild-typeto initiate valve morphogenesis.
Work in the past has shown that myocardial cells cushions in culture. We found that Cnb1 null explants
but not wild-type explants inhibited mesenchymal trans-produce signals that induce the adjacent endocardial
cells in the cushion to undergo mesenchymal differentia- formation in cocultured wild-type cushion explants (Fig-
ures 4D–4F). In addition, wild-type cushion explantstion (Eisenberg and Markwald, 1995) (Figure 4A). There-
fore, failure of mesenchymal transformation in embryos failed to induce mesenchymal transformation in the
Cnb1 null explants (Figure 4F), indicating that myocar-lacking myocardial NFATc signaling could be caused
either by the requirement for NFATc to produce an acti- dial explants deficient in calcineurin signaling produce
a soluble signal that inhibits mesenchymal transforma-vator of EMT or the NFATc-dependent suppression of
an inhibitor of mesenchymal transformation (Figures 4B tion in a paracrine fashion. We thus turned our attention
to the identification of this suppressor of EMT.and 4C). To distinguish between these possibilities, we
Cell
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Suppression of Myocardial VEGF Production early gestation, the yolk sac in the rodent provides little
impediment to the passage of macromolecules (Carpen-by Calcineurin Signaling Is Essential for
Endocardial Mesenchymal Transformation ter, 1980; Parr and Parr, 1986). This feature allowed us
to study the interactions between sFlt, VEGF, and CsA/To identify the soluble inhibitor of EMT, we defined
genes regulated by calcineurin/NFATc signaling at E9.5 FK506 in the embryo culture system.
Embryos cultured at E9.5 developed normally for atusing transcript arrays. Several secreted factors were
derepressed in calcineurin or NFATc mutant mice and least 24 hr and underwent normal EMT in the whole
embryo culture system (Figure 5A). As expected, CsA/were derepressed by CsA administration. One of the
candidates was vascular endothelial growth factor FK506 inhibited EMT in embryos cultured from E9.5 to
E10.5 (Figure 5B). VEGF, similar to the calcineurin inhibi-(VEGF) (Graef et al., 2001). Given that transgenic overex-
pression of VEGF in myocardium at E9 inhibits EMT (Dor tors, inhibited this transformation process, leaving the
endocardial cushion devoid of mesenchymal cells (Fig-et al., 2001), we hypothesized that VEGF might be the
inhibitor of mesenchymal transformation. To test this ure 5E). Soluble Flt, which alone did not have significant
effects on the development of embryos cultured fromhypothesis, we used recombinant soluble Flt protein
(sFlt), consisting of the extracellular domain of the VEGF E9.5 to E10.5, rescued EMT inhibited either by cal-
cineurin inhibitors or VEGF (Figures 5A–5F), consistentFlt receptor (Kuo et al., 2001), to sequester and antago-
nize the action of VEGF. We found that sFlt rescued EMT with our observations in the in vitro EMT assay. The
absence of EMT in embryos exposed to CsA/FK506 isin cushion explants treated with CsA (Figures 4G–4J). It
also rescued EMT in explants with Cnb1 null mutation not secondary to growth delay caused by angiogenic
defects in the yolk sac/embryos since no such defects(Figure 4K). In contrast, TGF-3, a signal essential for
EMT, did not reverse the effect of CsA or Cnb1 mutation were observed when embryos were treated with CsA/
FK506 from E9.5 to E10.5 (data not shown). This is con-(data not shown), suggesting that the action of sFlt was
specific for calcineurin/NFATc. Similar to CsA, VEGF sistent with the previous report that calcineurin is re-
quired for angiogenesis between E7 and E8 (Graef et al.,strongly inhibited EMT of the E9.5 cushion explants but
did not have a significant effect on the proliferation or 2001). Therefore, these data provide additional in vivo
evidence that suppression of myocardial VEGF produc-migration of mesenchymal cells of E10.5 explants (Fig-
ure 4L). Inhibition of EMT by VEGF was reversed by sFlt tion by calcineurin is essential to initiate EMT in intact
embryos.in a dose-dependent manner (Figure 4M and data not
shown). Similarly, sFlt rescued CsA-inhibited EMT (Fig-
ure 4N), indicating that CsA’s effect on EMT was medi- Calcineurin Control of VEGF Is Conserved in Fish
Heart Valve Morphogenesisated through VEGF. To further study the role of VEGF
at physiological levels, we added 0.2 nM sFlt to normal To study whether the requirement for calcineurin signal-
ing in heart valve development is conserved across evo-E9 cushion explants, fully blocking endogenous VEGF
signaling. We found that this higher dose of sFlt en- lution, we performed FK506 treatment and washout ex-
periments on zebrafish. We found that calcineurin washanced EMT by 2- to 3-fold (Figure 4N), suggesting that
VEGF was functioning at physiologic levels in the cush- most crucial for heart valve formation between 22 and
30 hpf in the zebrafish embryos (Figures 5G and 5H).ion to keep EMT in check. These data indicate that
calcineurin/NFATc signaling normally suppresses VEGF Zebrafish treated with CsA/FK506 between 22 and 30
hpf developed congestive heart failure with swelling ofin the cushion to allow endocardial-mesenchymal trans-
formation. pericardial sacs (Figures 5H–5K). The ventricular myo-
cardium in the fish appeared thin and abnormally formed,The early essential roles of VEGF in angiogenesis (Car-
meliet et al., 1996; Ferrara et al., 1996) and placental consistent with a conserved role of calcineurin in myo-
cardial hypertrophy (Molkentin et al., 1998). Most impor-development (Reynolds and Redmer, 2001) prevented
us from studying VEGF knockout mutants or the interac- tantly, heart valves failed to develop in the atrioventricu-
lar canal and cardiac outflow tract (Figure 5N and datations between calcineurin and VEGF in utero. Instead,
we employed a whole embryo culture system in which not shown), indicating that calcineurin is essential for
fish valve morphogenesis.embryos can survive and develop for at least 1 day
without placental support (Sturm and Tam, 1993). During To study whether calcineurin suppression of VEGF
Figure 4. Suppression of VEGF by Calcineurin Is Essential for EMT In Vitro
(A–C) Myocardial-endocardial signaling (green nuclei) in the cushion is required for EMT. Myocardial calcineurin/NFATc signaling may direct
EMT either by producing an activator (B) or by repressing an inhibitor (C) of EMT.
(D) Mesenchymal cell outgrowth (arrow) from a control E9.5 endocardial cushion.
(E) EMT of two wild-type cushions cultured adjacently (arrows).
(F) EMT of adjacently cultured Cnb1/ and wild-type cushion explants.
(G) EMT in an untreated E9.5 cushion explant.
(H) EMT in an E9.5 cushion explant treated with CsA.
(I) EMT in an E9.5 cushion explant treated with CsA and sFlt.
(J) Quantitation of EMT in E9.5 explants treated with CsA, sFlt, or both.
(K) Quantitation of EMT in E9.5 Cnb1/, and wild-type explants with or without sFlt.
(L) Quantitation of EMT in VEGF-treated or untreated explants from WT E9.5 and E10.5 embryos.
(M) Quantitation of EMT in E9.5 explants treated with VEGF, sFlt, or both.
(N) Dose response of EMT rescued by sFlt.
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Figure 5. Calcineurin Suppression of VEGF Is Essential for EMT In Vivo
(A and D) EMT in the atrioventricular canal (AVC) of control embryo cultured from E9 to E10 in whole embryo culture system.
(B) EMT in AVC of embryos cultured from E9 to E10 in the presence of CsA and FK506.
(C) EMT in AVC of embryos cultured from E9 to E10 in the presence of CsA, FK506, and sFlt.
(E) EMT in AVC of embryos cultured from E9 to E10 in the presence of VEGF.
(F) EMT in AVC of embryos cultured from E9 to E10 in the presence of VEGF and sFlt.
(G) Schematic representation of the critical period during which calcineurin is required for fish valve formation.
(H) Pericardial swelling induced by addition of CsA/FK506 at different stages of zebrafish development.
(I) Pericardial size of control and CsA/FK506-treated zebrafish with or without sFlt.
(J–O) Gross and histological abnormalities in pericardial sac and AVC of untreated (J and M), CsA- or FK506-treated (K and N), and CsA/
FK506 and sFlt-treated (L and O) zebrafish. A, atrium; V, ventricle.
was also required in zebrafish for heart valve formation, with the gestational age of the embryos from E10 to
E12 (data not shown). In contrast, VEGF was stronglywe performed rescue experiments using sFlt to antago-
nize VEGF activity. Indeed, sFlt rescued valvular defects expressed in the myocardium of Cnb1-deficient E9.0
embryos (Figure 6E) or c2/c3/c4 mutants (Figure 6G),in zebrafish treated with CsA or FK506 (Figures 5L and
5O). These studies raised the question of the mechanism suggesting that VEGF was normally repressed by cal-
cineurin/NFATc during this period. Derepression ofof calcineurin/NFATc repression of VEGF production.
VEGF expression in Cnb1 or NFATc2/c3/c4 null embryos
occurred only in the myocardial and not in the endocar-Calcineurin/NFATc Signaling Represses
dial cells (Figures 6F and 6H), consistent with the essen-the Transcription of the VEGF Gene
tial role of myocardial calcineurin to repress VEGF andTo learn how calcineurin/NFATc regulates the expres-
initiate valve formation. Transcript array analysis showedsion of VEGF, we first used RNA in situ hybridization
elevated VEGF mRNA in embryos lacking Cnb1 (Graefto analyze VEGF-A mRNA expression in explants and
et al., 2001) or c2/c3/c4 (Figure 6I). CsA also increasedembryos. We found that endocardial cushion explants
VEGF protein expression in E9 embryonic hearts cul-treated with CsA in vitro had highly elevated VEGF
tured on collagen gel (Figure 6J). Embryos exposed tomRNA expression in the myocardium compared to con-
CsA in utero also had elevated VEGF expression bytrols (Figures 6A–6C). CsA, by inhibiting calcineurin/
RNAase protection assay, transcript array analysisNFATc activity, was therefore capable of derepressing
(Graef et al., 2001), and ELISA analysis (Figure 6J), sug-VEGF mRNA levels in the myocardium, suggesting a
gesting that CsA derepressed VEGF expression in utero.repressor function of NFATc in the regulation of VEGF
These observations indicate that calcineurin and NFATcexpression. In wild-type mice, myocardial VEGF expres-
signaling suppress VEGF production and led us to inves-sion was low at E9.0 of development (Figure 6D), when
tigate the mechanism of this repression.EMT was most sensitive to the inhibition by CsA or
To study the molecular basis underlying the repres-VEGF. VEGF expression became detectable in the myo-
sion of VEGF by calcineurin/NFATc, we sought a cellcardium by early E10 (data not shown), at a time after
culture system that would closely reflect the derepres-EMT had taken place and cushion mesenchymal cells
sion of VEGF observed in embryos deficient in this path-were refractory to the effect of CsA or VEGF. VEGF
expression subsequently increased in the myocardium way. We found that treatment of primary mouse embry-
NFAT Signaling in Heart Valve Morphogenesis
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Figure 6. Calcineurin/NFATc Signaling Represses the Transcription of VEGF-A
(A) Plane of sections through cushion explants in (B) and (C). (B–H) VEGF in situ hybridization in explants, control and mutant embryos (brown,
VEGF-A RNA staining; blue, hematoxylin counterstaining). (B) VEGF expression in untreated cushion explants. (C) VEGF expression in CsA-
treated cushion explants. (D) VEGF expression in the cardiac region of control E9.0 embryo. (E) VEGF expression in the cardiac region of
Cnb1/ E9.0 embryo. (F) Higher magnification of (E). Arrows, myocardial cells; arrowheads, endocardial cells. (G) VEGF expression in cardiac
region of NFATc2/c3/c4 triple null E9.0 embryo. (H) Higher magnification of (G). Arrows, myocardial cells; arrowheads, endocardial cells. (I)
Transcript array analysis of VEGF-A in Cnb1 and c2/c3/c4 null embryos. (J) VEGF-A protein secretion in embryonic heart culture treated with
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onic fibroblasts (MEFs) with CsA resulted in increased the repression of the VEGF promoter by NFATc4. In
contrast, c4nuc activated luciferase expression driven bylevels of VEGF in the culture media (Figure 6K). The lag
time until VEGF could be detected in the media following the IL-2 NFAT binding sites about 100-fold in the same
cells (Figure 7E). Therefore, the ability of NFATc to actCsA/FK506 treatment was about 2 hr (Figure 6K). Since
about 1–2 hr are generally required for transcription, as a repressor is promoter dependent.
To assess whether endogenous NFATc proteins formtranslation, and secretion, these kinetics of VEGF dere-
pression are consistent with a direct role for NFAT tran- complexes on the VEGF promoter, we performed chro-
matin immunoprecipitation assays (Weinmann et al.,scription complexes in repressing the VEGF gene.
NFAT transcription complexes bind to composite 2001) using MEFs. The VEGF promoter region flanking
the m2400 site could be immunoprecipitated with anti-sites that serve to integrate Ca2 signaling with other
pathways (Crabtree, 1989; Durand et al., 1988; Shaw et NFATc4 antibody in wild-type MEFs but not in MEFs
lacking NFATc2/c4 or treated with CsA and FK506al., 1988). The VEGF-A genes of human, rat, and mouse
(Figure 7A) contain multiple conserved putative NFATc (Figure 7F). Thus, endogenous NFATc4 proteins form
transcriptional complexes on the VEGF promoter. Inbinding sites (GGAAA) (Supplemental Figures S3D and
S3E). Oligonucleotides with 10 bases flanking each core contrast to the m2400 site, the nonfunctional site
(m8041) (Supplemental Figures S3D–S3F) on the VEGFGGAAA sequence were synthesized and used in electro-
phoretic mobility shift assay (EMSA) to study NFATc promoter could not be immunoprecipitated (Figure 7F),
and the less potent NFAT binding site m3243 was onlybinding (Figure 7B) (Chang et al., 1995; Ho et al., 1995).
Of the 11 candidate sites, two (m3243 and m2400) weakly detectable (data not shown). The IL-2 promoter
NFAT site, which is not active in MEFs, was not precipi-bound recombinant NFATc3 and c4 proteins (Figure 7C,
lanes 1 and 6). The observed complexes contained tated by anti-NFATc4 antibody (Figure 7F), indicating
that endogenous NFAT complexes form specifically onNFATc proteins as they were supershifted with an anti-
body recognizing the protein (Figure 7C, lanes 2 and 7). the m2400 site of the VEGF promoter. Taken together,
these data suggest that endogenous calcineurin/NFATcThe formation of NFATc3-DNA complexes was dis-
rupted by an excess of unlabeled competitor oligo directly represses the transcription of the VEGF-A gene.
(m3243, m2400) (Figure 7C, lanes 3 and 8) but not
by excess competitor oligo with GGAAA to GGAGC mu- Discussion
tation in the core sites (m3243 mut, m2400 mut)
(Figure 7C, lanes 4 and 9). This GGAGC core site muta- During early heart development, the primitive endocar-
dial cushion serves as a valve because the primary myo-tion reduced NFATc3 binding (Figure 7C, lanes 5 and
10). None of the other nine candidate sites, such as cardium surrounding the cushion contracts rhythmically
to occlude the heart lumen during the cardiac cycle tom-1592, was bound by NFATc3 (Figure 7C, lane 11,
and data not shown). NFATc3 bound at subnanomolar prevent blood reflux (Moorman et al., 1998). This early
primitive valve function is calcineurin independent, asconcentrations to the VEGF-A m2400 site with sub-
stantially higher affinity than the canonical NFAT site in embryos lacking calcineurin have normal sequential
atrial ventricular contraction and unidirectional flowthe IL-2 promoter (mIL2) (Shaw et al., 1988) (Figure 7D).
NFATc3 bound the m3243 site at an affinity compara- without blood regurgitation (data not shown). As the
heart enlarges during development, the rhythmic con-ble to mIL2 site binding, suggesting that the binding of
NFATc3 to these sites is specific and strong enough to tractions of primitive cushions are insufficient to occlude
the heart lumen. At this point, valve development isbe physiologically relevant.
We defined the regions of the VEGF gene mediating essential, and a requirement of calcineurin/NFAT signal-
ing becomes apparent.CsA- and NFATc4-dependent repression using lucifer-
ase reporter assays in MEFs. Transfection of a constitu-
tively nuclear/active form of NFATc4 (c4nuc) (Graef et Initiation of Heart Valve Morphogenesis Requires
Calcineurin/NFATc Suppression of VEGFal., 1999) repressed the transcription dependent on the
753 to 2836 sites of VEGF promoter by about 2-fold Expression in the Myocardium
Valve morphogenesis begins with the transformation of(Figure 7E). Mutation of the core NFAT binding site at
m2400 from GGAAA to GGAGC prevented the repres- cushion endocardial cells into mesenchymal cells. Mice
lacking Cnb1 or treated with CsA at E9 overexpresssion of VEGF promoter by c4nuc (Figure 7E). These results
indicate that the m2400 NFAT binding site can mediate VEGF in the myocardium, resulting in a failure of EMT.
Figure 7. NFATc Transcriptional Factors Directly Repress the VEGF Promoter Activity
(A) Conserved GGAAA sites in the upstream regulatory sequence and first intron of the VEGF-A genes of human, rat, and mouse. (B) Probes
used in the electrophoretic mobility shift assay (EMSA) in (C) and (D). The numbers denote the genomic position of core sites relative to the
start codon of VEGF-A gene. (C) EMSA using specific probes and NFATc3 recombinant proteins (5 nM) tagged with EE peptide. Asterisks,
32P-labeled probes; -EE, monoclonal antibody specific for the EE tag. (D) EMSA of NFATc3 and DNA probes at various concentration of
NFATc3. (E) Luciferase activity in MEFs transfected with a luciferase reporter gene driven by the VEGF or IL-2 promoter in the presence or
absence of NFATc4. (F) Chromatin immunoprecipitation assay in wild-type, NFATc2/c4/, or CsA/FK506-treated MEFs. The 160 bp fragment
spans m2400. Primers are described in the text and in Supplemental Figure S3F. (G) A field of calcineurin/NFATc signaling in the myocardium
and endocardium directs heart valve morphogenesis. At E9, calcineurin/NFATc functions in the myocardium to repress VEGF expression,
permitting the overlying endocardial cells to undergo mesenchymal transformation and initiate heart valve morphogenesis. Later, at E11,
calcineurin/NFATc signaling is required again, this time in the endocardium, to direct mesenchymal development during the process of valvular
elongation. (H) Working model for the repression of VEGF by calcineurin/NFATc signaling.
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VEGF repression requires NFATc2/c3/c4 activity since tribute significantly to valve elongation. Although a very
low but functional level of NFATc1 in the cushion mesen-mice with targeted mutations in each of NFATc2/3/4
overexpress VEGF in the myocardium. Calcineurin/NFATc chyme cannot be completely excluded, these data
strongly suggest that endocardial but not mesenchymalsignaling, by repressing myocardial VEGF expression,
directs the overlying endocardial cells to transform into NFAT signaling is essential to direct the remodeling of
cushion mesenchyme into slender valvular leaflets.mesenchymal cells and initiate valve morphogenesis
(Figure 7G). Our conclusions are consistent with the
observation that transgenic overexpression of VEGF in Calcineurin/NFATc Functions within a Field
the myocardium at E9 disrupts the mesenchymal trans- or Morphogenetic Unit to Initiate and Perpetuate
formation process in vivo, resulting in embryonic lethal- Heart Valve Morphogenesis
ity (Dor et al., 2001). The myocardial and endocardial cells at the site of pro-
Discovered as a tumor-secreted protein (Dvorak et al., spective valve formation are sufficient to generate mes-
1979), vascular permeability factor (VPF)/VEGF-A exerts enchymal cells, which are later refined by signals from
highly dosage-sensitive roles in multiple developmental the overlying endocardium. Beyond the sites of valve
processes. Loss of one allele of VEGF results in vascular formation, myocardial and endocardial cells of the atria
defects and embryonic lethality (Carmeliet et al., 1996; and ventricles have no capacity to induce or become
Ferrara et al., 1996; Haigh et al., 2000). Moderate in- mesenchymal cells (Brown et al., 1999). Therefore, the
crease (2- to 3-fold) in endogenous VEGF expression endocardial cushion and adjacent myocardium consti-
leads to embryonic lethality at midgestation due to ab- tute a morphogenetic unit (blue area in Figure 7G) that
normal myocardial development and defective septal gives rise to heart valves. Our studies indicate that NFAT
formation (Miquerol et al., 2000). Our findings indicate signaling operates within this morphogenetic unit, first
that NFAT signaling directly suppresses VEGF expres- in the myocardium and then in the endocardium to con-
sion in the heart at the initial phase of heart valve mor- tribute to the formation of heart valves (Figure 7G). This
phogenesis when VEGF is widely expressed elsewhere mechanism is also conserved in zebrafish, illustrating
for embryonic angiogenesis and other developmental the importance of NFAT signaling in vertebrate heart
processes (Miquerol et al., 1999). valve development.
Why should a field of calcineurin/NFATc function in
adjacent tissues be essential to both initiate and propa-Refinement of Heart Valve Morphogenesis
Requires Endocardial but Not Mesenchymal gate morphogenesis of heart valves? One possibility
is that there are two distinct signals that sequentiallyCalcineurin/NFATc Signaling
Remodeling the heart valve leaflets requires signaling activate first myocardial and then endocardial NFATc
at specific times of valve development. Alternatively, ainteractions between the endocardial cells and underly-
ing mesenchymal cells. Our studies demonstrate that “master” signal may activate myocardial NFATc leading
to VEGF repression and the transcription of a secretedendocardial calcineurin/NFATc1 is required at E11 to
direct heart valve elongation. In contrast, autonomous molecule that in turn activates endocardial NFATc1. In
this second mechanism, only one signal is required tocalcineurin/NFATc signaling in the cushion mesen-
chyme may not contribute significantly to the remodel- order the sequence of NFATc signaling for valve forma-
tion. The initial signal could be provided by Wnt and/oring process, based on the following observations. First,
expressing NFATc1 in the endocardial cells of NFATc1/ mechanical cues resulting from hemodynamic stress as
the embryo develops. A third possibility is that localmice completely rescued the valvular defects, indicating
that NFATc1 in the cushion mesenchyme is not essential production of a soluble, membrane-permeable molecule
(blue area in Figure 7G) regulates an NFAT nuclear part-for valve remodeling. This is further supported by the
observation that NFATc1 proteins became inactivated ner protein (NFATn) (Figure 7H). Since NFAT activity
depends on activation of both NFATc and NFATn, suchand exported to the cytoplasm as the endocardial cells
delaminated from the surface during EMT (Supplemen- a mechanism could specifically coordinate NFAT func-
tion in two adjacent tissues.tal Figure S1E), and the expression of NFATc1 was rap-
idly repressed as the mesenchymal cells migrated into How do the requirements for NFAT signaling relate to
other known requirements for heart valve formation?the cushion (Supplemental Figure S1E). Consistent with
this observation, a recent study shows that NFATc1 TGF-3, essential for avian EMT (Nakajima et al., 2000;
Ramsdell et al., 1998), does not rescue EMT in cushionexpression in the cushion mesenchyme is suppressed
by the Sox9 pathway (Akiyama et al., 2004), suggesting explants treated with CsA, suggesting that TGF-3 does
not act downstream of calcineurin/NFATc signaling forthat repression of NFATc1 signaling in mesenchymal
cells may be physiologically important for cushion mes- EMT. More likely, TGF- signaling represents a second
pathway essential and parallel to NFAT repression ofenchyme to develop. Second, mice in which Cnb1 was
deleted in both endocardial and mesenchymal cells VEGF. Recent evidence suggests that Wnt/-catenin
signaling may help localize the site of valve formation(Supplemental Figure S1D) displayed valvular defects
identical to mice lacking NFATc1, which is active only (Hurlstone et al., 2003). Hence, Wnt signaling could act
upstream of NFATc2/c3/c4.in the endocardium. This suggests that calcineurin in
the mesenchyme makes no additional contribution to A major goal of modern developmental biology is the
recapitulation of development for regenerative or thera-heart valve remodeling. Third, embryos exposed to CsA
in utero (Figure 2) had valvular defects almost identical peutic purposes. Since heart valve malformations are
the most common human congenital abnormalities, thisto mice lacking endocardial Cnb1 or NFATc1, suggest-
ing that myocardial or mesenchymal Cnb1 does not con- goal is particularly salient. The understanding that cal-
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construct using the Dual-Luciferase Reporter Assay System (Pro-cineurin/NFATc signaling plays two sequential, critical
mega, Madison, WI).roles in the initiation and propagation of valve develop-
ment brings us closer to the goal of constructing a valve
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